Biocon has conducted a large share transaction on the National Stock Exchange, selling 1.37 million shares at around Rs. 349 each, resulting in an overall value of approximately Rs. 47.97 crores.

Biocon Ltd will attend the HSBC Global Investment Summit in Hong Kong and an investor roadshow in Singapore next April. Notably, the company has stated that it won't reveal any undisclosed price-sensitive information during these meetings. Further details can be found on Biocon's official website.

Biocon sets its sights on becoming a global frontrunner in insulin manufacturing, as declared by chairman Kiran Mazumdar-Shaw, amidst growing competition that is exploring innovative treatments such as GLP-1 drugs.

Biocon enters the U.S. market with two new biosimilar drugs, Bosaya and Aukelso. The FDA has granted interchangeable status for these products by September 2025, positioning them to tap into a $5 billion market valued in 2024.

Biocon's stock dropped by 4%, reaching ₹340.8, due to substantial trades on NSE possibly resulting from block deals. The pharmaceutical giant continues to aim for leadership in insulin and GLP-1 therapies, emphasizing affordability and global expansion.

Investors are suggested to hold onto Asian Paints and Dixon Tech in the short term due to oil price fluctuations and increased competition in ECMS. Biocon, BSE, DAM Capital, and Titagarh Rail, on the other hand, have been recommended as potential buys or holds, with specific price levels noted for profit opportunities.

The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.